Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
1 hedge funds and large institutions have $1 invested in Vyant Bio, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 16 closing their positions.
94% less funds holding
Funds holding: 17 → 1 (-16)
100% less capital invested
Capital invested by funds: $137K → $1 (-$137K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 16
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$27.4K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$22.5K |
| 3 |
MC
Mayo Clinic
Rochester,
Minnesota
|
-$16.1K |
| 4 |
BlackRock
New York
|
-$15.4K |
| 5 |
Millennium Management
New York
|
-$13K |
VYNT Hedge Fund Activity: Q2 2023 in Review
1 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q2 2023, worth a combined $1 — down 100% from $137K a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of VYNT and 0 opened new positions — a net loss of 16 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $27.4K sold.
- 1 institutional investor held Vyant Bio, Inc. Common Stock (VYNT) as of Q2 2023, down from 17 in Q1 2023.
- Funds reported $1 of Vyant Bio, Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Vyant Bio, Inc. Common Stock positions in Q2 2023 and 16 closed out, a net change of -16 holders.
- The largest Vyant Bio, Inc. Common Stock seller in Q2 2023 was Vanguard Group, an estimated $27.4K sold.
Based on aggregated 13F filings for Q2 2023.